A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

Study of post-myocardial infarction (heart attack) drug to prevent future cardiovascular events using interleukin anti-body to reduce cardiovascular inflammation

http://clinicaltrials.gov/ct2/show/study/NCT01327846?term=canakinumab+hsCRP&rank=1&show_locs=Y#locn

Sponsor: Novartis Pharmaceutical

Keywords: MI, myocardial infarction, heart attack, heart disease, heart, cardiac, canakinumab, Novartis, Cantos, anti-inflammatory, drug, cardiovascular

Cardiology (Heart)
Gerald Gacioch, MD
Active / Closed to Enrollment
Center for Clinical Research
585.922.3536